---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005181"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:38:02.197477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks

## Summary
- Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.
- Cash and securities $630.3M (down $43M QoQ); company expects runway through 2027.
- Phase 2 CSU barzolvolimab: up to 41% complete response at 76 weeks (7 months off-treatment); 48% no quality-of-life impact.
- Phase 3 CSU program (EMBARQ-CSU1/2) enrolling globally; Phase 2 CIndU and EoE data due in 2H 2025.
- Phase 1 CDX-622 (bispecific SCF/TSLP) in healthy volunteers: Part 1 data expected 2H 2025.

## SEC filing metadata
- accession: 0001171843-25-005181
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184325005181/0001171843-25-005181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184325005181/f8k_080625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005181
- JSON: https://secwatch.observer/filing/0001171843-25-005181.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.